Nicolas Daguindau

Interpretability of the Quantra viscoelastic test in patients with haematological malignancies presenting severe thrombocytopenia

Viscoelastic tests have been scarcely evaluated in patients with haematological malignancies and severe thrombocytopenia. The VISCOTHEM-1 study investigated the interpretability of Quantra results in these patients, with platelet count less than 50 × 109/l. The objective was to e...

End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial

In this ancillary study of the RELEVANCE phase III trial (NCT01650701), we performed the first direct intra-patient comparison of circulating tumor DNA (ctDNA)-based versus cellular t( BCL2 / JH ) translocation-based MRD at end of induction (EOI) in 278 patients with advanced FL,...

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN126...